AGENUS INC (AGEN) Quick Ratio
- Quick ratio · latest quarter: Value (m); Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30..
Quick ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | (m) | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | (m) | Cash and Cash Equivalents, at Carrying Value · Accounts Receivable, after Allowance for Credit Loss, Current |
| Current obligations | 231.82M USD | Liabilities, Current |
| Cash and equivalents | 18.74M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | |
| Customer receivables | 14.72M USD | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory · excluded from quick assets | (m) | Inventory, Net |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $231.82M | $18.74M | (m) | $14.72M | (m) | (m) |
| 2026-03-31 | (m) | $249.24M | $35.00M | (m) | $6.56M | (m) | (m) |
| 2025-12-31 | (m) | $323.49M | $3.00M | (m) | $1.83M | (m) | (m) |
| 2025-09-30 | (m) | $287.13M | $3.46M | (m) | $538.00K | (m) | (m) |
| 2025-06-30 | (m) | $234.56M | $9.53M | (m) | $709.00K | (m) | (m) |
| 2025-03-31 | (m) | $208.30M | $18.49M | (m) | $354.00K | (m) | (m) |
| 2024-12-31 | (m) | $221.40M | $40.44M | (m) | $407.00K | (m) | (m) |
| 2024-09-30 | (m) | $270.64M | $44.78M | (m) | $207.00K | (m) | (m) |
| 2024-06-30 | (m) | $270.67M | $93.72M | (m) | $719.00K | (m) | (m) |
| 2024-03-31 | (m) | $256.00M | $52.86M | (m) | $476.00K | (m) | (m) |
| 2023-12-31 | (m) | $255.90M | $76.11M | (m) | $25.84M | (m) | (m) |
| 2023-09-30 | (m) | $198.36M | $106.31M | (m) | $1.03M | (m) | (m) |
| 2023-06-30 | (m) | $204.07M | $143.21M | (m) | $1.34M | (m) | (m) |
| 2023-03-31 | (m) | $190.90M | $164.82M | (m) | $1.42M | (m) | (m) |
| 2022-12-31 | (m) | $188.95M | $178.67M | (m) | $2.74M | (m) | (m) |
| 2022-09-30 | (m) | $173.07M | $208.35M | (m) | $8.82M | (m) | (m) |
| 2022-06-30 | (m) | $159.72M | $228.38M | (m) | $18.99M | (m) | (m) |
| 2022-03-31 | (m) | $163.06M | $247.71M | (m) | $1.29M | (m) | (m) |
| 2021-12-31 | (m) | $156.94M | $291.93M | (m) | $1.52M | (m) | (m) |
| 2021-09-30 | (m) | $150.13M | $256.53M | (m) | $21.77M | (m) | (m) |
| 2021-06-30 | (m) | $168.75M | $73.54M | (m) | $1.44M | (m) | (m) |
| 2021-03-31 | (m) | $138.37M | $119.37M | (m) | $2.17M | (m) | (m) |
| 2020-12-31 | (m) | $129.88M | $99.87M | (m) | $1.16M | (m) | (m) |
| 2020-09-30 | (m) | $146.90M | $114.14M | (m) | $1.41M | (m) | (m) |
| 2020-06-30 | (m) | $142.27M | $79.17M | (m) | $16.63M | (m) | (m) |
| 2020-03-31 | (m) | $127.34M | $92.28M | (m) | $2.64M | (m) | (m) |
| 2019-12-31 | (m) | $122.21M | $61.81M | (m) | $16.29M | $0.00 | (m) |
| 2019-09-30 | (m) | $132.95M | $93.27M | (m) | $2.33M | $55.00K | (m) |
| 2019-06-30 | (m) | $121.74M | $121.72M | (m) | $2.21M | $55.00K | (m) |
| 2019-03-31 | (m) | $105.51M | $158.31M | (m) | $796.00K | $55.00K | (m) |
| 2018-12-31 | (m) | $68.06M | $53.05M | (m) | $938.14K | $55.49K | (m) |
| 2018-09-30 | (m) | $58.19M | $46.17M | (m) | $6.07M | $55.49K | (m) |
| 2018-06-30 | (m) | $51.32M | $43.16M | (m) | $10.92M | $55.49K | (m) |
| 2018-03-31 | (m) | $30.16M | $52.35M | (m) | $1.13M | $62.24K | (m) |
| 2017-12-31 | (m) | $56.44M | $60.19M | (m) | $1.13M | $79.49K | (m) |
| 2017-09-30 | (m) | $54.41M | $65.08M | (m) | $2.19M | $80.24K | (m) |
| 2017-06-30 | (m) | $32.91M | $81.83M | (m) | $3.94M | $87.00K | (m) |
| 2017-03-31 | (m) | $36.35M | $113.86M | (m) | $6.77M | $87.45K | (m) |
| 2016-12-31 | (m) | $40.85M | $71.45M | (m) | $11.35M | $88.20K | (m) |
| 2016-09-30 | (m) | $34.85M | $75.44M | (m) | $10.28M | $88.20K | (m) |
| 2016-06-30 | (m) | $33.06M | $73.40M | (m) | $9.42M | $88.20K | (m) |
| 2016-03-31 | (m) | $31.26M | $78.33M | (m) | $10.22M | $88.20K | (m) |
| 2015-12-31 | (m) | $28.93M | $136.70M | (m) | $9.80M | $88.20K | (m) |
| 2015-09-30 | (m) | $28.29M | $184.14M | (m) | $7.33M | $88.20K | (m) |
| 2015-06-30 | (m) | $25.32M | $124.66M | (m) | $4.11M | $88.20K | (m) |
| 2015-03-31 | (m) | $21.00M | $79.30M | (m) | $2.53M | $88.20K | (m) |
| 2014-12-31 | (m) | $9.23M | $25.71M | (m) | $0.00 | $95.70K | (m) |
| 2014-09-30 | (m) | $15.61M | $38.39M | (m) | $0.00 | $95.70K | (m) |
| 2014-06-30 | (m) | $18.57M | $48.27M | (m) | $0.00 | $95.70K | (m) |
| 2014-03-31 | (m) | $14.37M | $73.49M | (m) | $0.00 | (m) | (m) |
| 2013-12-31 | (m) | $10.30M | $27.35M | (m) | $1.20K | $0.00 | (m) |
| 2013-09-30 | (m) | $9.65M | $30.20M | (m) | $1.13K | $3.27K | (m) |
| 2013-06-30 | (m) | $7.18M | $13.44M | (m) | $202.49K | $4.02K | (m) |
| 2013-03-31 | (m) | $5.78M | $17.21M | (m) | $163.73K | $16.02K | (m) |
| 2012-12-31 | (m) | $4.81M | $21.47M | (m) | $552.33K | $16.02K | (m) |
| 2012-09-30 | (m) | $4.83M | $24.76M | (m) | $369.06K | $16.02K | (m) |
| 2012-06-30 | (m) | $4.59M | $25.46M | (m) | $92.29K | $18.57K | (m) |
| 2012-03-31 | (m) | $5.51M | $24.59M | (m) | $58.72K | $18.57K | (m) |
| 2011-12-31 | (m) | $4.75M | $10.75M | (m) | $0.00 | $20.07K | (m) |
| 2011-09-30 | (m) | $5.87M | $14.73M | (m) | $0.00 | $26.43K | (m) |
| 2011-06-30 | (m) | $4.81M | $12.02M | (m) | $188.00 | $26.43K | (m) |
| 2011-03-31 | (m) | (m) | $10.63M | (m) | (m) | (m) | (m) |
| 2010-12-31 | (m) | $5.42M | $19.78M | (m) | $35.00K | $26.43K | (m) |
| 2010-09-30 | (m) | (m) | $14.41M | (m) | (m) | (m) | (m) |
| 2010-06-30 | (m) | (m) | $18.75M | (m) | (m) | (m) | (m) |
| 2009-12-31 | (m) | (m) | $20.07M | (m) | (m) | (m) | (m) |
| 2008-12-31 | (m) | (m) | $24.47M | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |